Adam H. Schechter, President and Chief Executive Officer of Labcorp Holdings Inc (NYSE: LH), completed a sale of 8,705 shares of the company’s common stock on March 3, 2026. The shares moved at a price of $279.9595 each, producing proceeds of approximately $2.44 million. After this disposition, Schechter retains direct ownership of 80,773 Labcorp shares.
The share sale comes at a time when Labcorp's stock sits close to its 52-week high of $293.72 and has gained about 12% year-to-date. Current market data show the stock trading at a price-to-earnings ratio of 26.91, while the company’s market capitalization stands at approximately $23.1 billion.
Investors are also parsing Labcorp’s latest quarterly report. For the fourth quarter of 2025 the company recorded earnings per share of $4.07, topping the consensus expectation of $3.93. Revenue for the quarter measured $3.52 billion, falling short of the $3.56 billion that had been anticipated.
In addition to the financial results, Labcorp disclosed an expanded collaboration with PathAI. Under the arrangement, Labcorp will implement the AISight Dx digital pathology platform across its national network of anatomic pathology laboratories and hospital collaborations. The platform is described as FDA-cleared and cloud-based, enabling pathologists to handle slides in a digital workflow and to leverage artificial intelligence as a diagnostic aid.
Taken together, the insider sale, mixed quarterly performance and the strategic technology rollout represent the most recent developments investors are monitoring. The stock's valuation measures and market capitalization provide context for the insider transaction, while the financial results and the PathAI partnership feed into assessments of Labcorp’s operational trajectory.
Context limitations: The company’s broader strategic plans, executive intentions behind the sale, and any additional details about the timing or structure of the PathAI implementation were not provided in the company's disclosures referenced here.